Aug 12, 2020
Dietrich Stephan PhD, CEO, NeuBase Therapeutics discusses the history of research into the genetic basis of all diseases, NeuBase's PATrOL™ platform allowing for intelligent design of drugs that engage with a malfunctioning gene, and the company's therapies in development for Huntington's disease and myotonic dystrophy, which Dr. Stephan describes as "heat seeking missiles" because they are so specific and targeted to the broken gene of interest.
@NeuBaseinc #RareDisease #GeneSilencing #HuntingtonsDisease #DM1 $NBSE